| Literature DB >> 20209339 |
Regina Célia Moreira1, Marta Mitiko Deguti, Marcilio Figueiredo Lemos, Cláudia Patara Saraceni, Isabel Takano Oba, Angela Maria Miranda Spina, Alessandra Stilhano Nascimento-Lima, Jorge Fares, Raymundo Soares Azevedo, Michele Soares Gomes-Gouvêa, Flair José Carrilho, João Renato Rebello Pinho.
Abstract
The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among haemodialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45) of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20209339 DOI： 10.1590/s0074-02762010000100017
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN： 0074-0276 Impact factor: 2.743